|
⚲
|
| Keyboard |
| Camber Capital Management LLC
✚
|
|
|---|---|
| CRD # | 155454 |
| SEC # | 801-73594 |
| CIK # | 0001444043 |
| AUM | |
| Employees | 10 (60% Investors, 0% Brokers) |
| Fees | |
| Minimum | |
| Phone | 617-717-6600 |
| Address | 101 Huntington Avenue Boston, MA 02199-8089 |
| Source | [IAPD] [EDGAR] [Website] |
| Total AUM ($B) |
|---|
| Fees and Compensation — Form ADV Part 2A (6/11/2018) [Brochure] |
|---|
Item 5: Fees and Compensation
A. Description
Camber bases its fees and performance compensation upon a percentage of assets under
management and upon performance. Clients typically pay Camber quarterly management fees no
greater than 1.5% per annum of the balance in such Client's account or the net asset value of each
investor’s investment in a Client organized as a pooled investment vehicle. Clients also pay or allocate
to an affiliate of Camber a performance allocation or fee equal to no greater than twenty percent
(20%) of the increase in net asset value of a Client’s account or of the increase in the net asset value
of an investor’s investment in a Client organized as a pooled investment vehicle (after calculation and
accrual of management fees) generally determined as of the last business day of each fiscal year,
subject to a high water mark. Such fees and compensation are currently not negotiable.
B. Fee Billing
Management fees are deducted quarterly from Clients' assets in advance. Any performance
allocation is deducted annually in arrears (or at the time of withdrawal if such withdrawal occurs prior
to the end of a year) from Clients' assets.
C. Other Fees and Expenses
Each Client managed by Camber pay or reimburse Camber, as the case may be, for all costs
and expenses related to its investments and its operations, including, without limitation, brokerage
and other transaction costs, clearing and settlement charges, interest and commitment fees on debit
balances or borrowings, borrowing charges on securities sold short, costs of any liability insurance
obtained on behalf of such Client, custody fees, costs of any litigation or investigation involving Client
activities, indemnification expenses, the management fees, consulting expenses, the fees and
expenses of professionals providing services to such Client, including legal, audit, accounting, tax and
administration and director services for Camber's non-U.S. pooled investment vehicles that are
organized as limited companies, any issue or transfer taxes chargeable in connection with any
securities transactions, any entity level taxes, regulatory costs, filing and license fees, the costs of
reporting and providing information and any extraordinary expenses. Camber or one of its affiliates
may elect from time to time to pay certain of a Client's expenses in addition to the organizational
expenses, including, but not limited to, other operating expenses. Please refer to Item 12 for more
information about brokerage.
D. Fees in Advance
Clients pay management fees quarterly and in advance. Management fees are calculated
based on the balance in each Client's account or net asset value of an investor’s investment in a Client
organized as a pooled investment vehicle as of the beginning of each calendar quarter. An investor
who invests in a pooled investment vehicle managed by Camber who withdraws shall be reimbursed
a pro rata portion of the management fee, if any, based upon the date of withdrawal. In addition, a
managed account Client who terminates its investment management agreement with Camber shall
be reimbursed a pro rata portion of any management fees paid in advance based upon the date of
termination.
E. Securities Compensation
Not applicable. |
| Account Minimums and Types of Clients — Form ADV Part 2A (6/11/2018) [Brochure] |
|---|
Item 7: Types of Clients Description Camber currently provides investment advisory services and portfolio management on a discretionary basis for high net worth individuals and pooled investment vehicles. Account Minimums The Clients that Camber manage have minimum initial investments of $1,000,000, although when Camber is accepting new managed accounts or investors in its pooled investment vehicles, Camber may accept lesser amounts in its sole discretion. |
| Sector | Form 13F Holdings | Value ($B) | |
|---|---|---|---|
| Zimmer Holdings Inc | 0.1 | ||
| Baxter International Inc | 0.1 | ||
| Humana Inc | 0.1 | ||
| CVS Caremark Corp | 0.1 | ||
| Globus Medical Inc | 0.0 | ||
| Icon PLC /Adr/ | 0.0 | ||
| Ascendis Pharma A/S | 0.0 | ||
| Merck & Co Inc | 0.0 | ||
| GlaxoSmithKline PLC | 0.0 | ||
| Pfizer Inc | 0.0 | ||
| View All | |||
| Holdings by Sector ($B) |
|---|
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| HF | Camber Capital Opportunity Fund LP | [2016-07-20] | 54.9 M | 0.0 M |
| Filed 2016-06-20 (D) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $1,000,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| HF | Camber Capital Fund LP | [2012-02-14] | 1,205.9 M | 655.5 M |
| Filed 2025-06-04 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $1,000,000 · Remaining Indefinite · Duration One year or less · Net Assets Decline to Disclose | ||||
| HF | Camber Capital Offshore Fund Ltd | [2012-02-14] | 1,629.3 M | 764.3 M |
| Filed 2025-06-04 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $1,000,000 · Remaining Indefinite · Duration One year or less · Net Assets Decline to Disclose | ||||
| AUM Breakdown | Accounts | AUM ($B) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 5 | 2.6 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 1 | 0.0 |
| Total | 6 | 2.6 |
| By Discretionary | ||
| Discretionary | 6 | 2.6 |
| Non-Discretionary | 0 | 0.0 |
| Total | 6 | 2.6 |
| By Non-United States Persons | ||
| Non-United States Persons | 0.0 | |
| United States Persons | 2.6 | |
| Total | 6 | 2.6 |
| Form D Directors | Role | # Filings | # Firms | 2011 - 2026 |
|---|---|---|---|---|
| Roger Hanson | Director | 255 | 86 | |
| Alaina Danley | Director | 111 | 32 | |
| Michael McDonald | Director | 123 | 30 | |
| Amber Ramsey | Director | 72 | 30 | |
| Stephen Dubois | Director, Executive Officer | 4 | 2 | |
| Camber Capital Management LLC | Promoter | 4 | 2 | |
| Camber Capital Partners LLC | Promoter | 3 | 2 | |
| Camber Capital Management LP | Promoter | 3 | 2 | |
| Camber Capital Partners III LLC | Executive Officer | 1 | 1 |
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 13F-HR | [0001444043] | |
| 3 | [0001444043] | |
| 4 | [0001444043] | |
| SC 13D | [0001444043] | |
| SC 13G | [0001444043] |
| Firm Profile (Form ADV) | |
|---|---|
| Discretionary AUM | $1.7B |
| Serves | Institutional, Retail |
| Fund Types | Hedge Fund |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
ZimVie Inc ZIMV
Common Stock
|
2024-08-02 | Sell | 525,000 | $17.71 | 9,297,750 |
|
AMAG Pharmaceuticals Inc AMAG
Common Stock
|
2020-10-01 | Sell | 4,390,000 | $13.57 | 59,572,300 |
|
AMAG Pharmaceuticals Inc AMAG
Common Stock
|
2019-08-09 | Buy | 26,600 | $8.94 | 237,804 |
|
AMAG Pharmaceuticals Inc AMAG
Common Stock
|
2019-08-09 | Buy | 3,400 | $9.18 | 31,212 |
|
AMAG Pharmaceuticals Inc AMAG
Common Stock
|
2019-08-07 | Buy | 4,000 | $7.58 | 30,320 |
|
AMAG Pharmaceuticals Inc AMAG
Common Stock
|
2019-08-07 | Buy | 301,000 | $7.79 | 2,344,790 |
|
AMAG Pharmaceuticals Inc AMAG
Common Stock
|
2019-08-07 | Buy | 50,000 | $7.74 | 387,000 |
|
Protalix BioTherapeutics Inc PLX
Common Stock
|
2016-12-02 | Sell | 2,500,000 | $0.32 | 800,000 |
|
Cardiovascular Systems Inc CSII
Common Stock
|
2016-09-20 | Sell | 57,000 | $23.54 | 1,341,780 |
|
Cardiovascular Systems Inc CSII
Common Stock
|
2016-09-19 | Sell | 1,043,000 | $23.25 | 24,249,750 |
|
Cardiovascular Systems Inc CSII
Common Stock
|
2016-02-23 | Buy | 250,000 | $7.55 | 1,887,500 |
|
Sequenom Inc SQNM
Common Stock
|
2016-01-04 | Buy | 75,000 | $1.59 | 119,250 |
|
Sequenom Inc SQNM
Common Stock
|
2015-12-31 | Buy | 395,435 | $1.64 | 648,513 |
|
Sequenom Inc SQNM
Common Stock
|
2015-12-30 | Buy | 195,000 | $1.59 | 310,050 |
|
Sequenom Inc SQNM
Common Stock
|
2015-12-15 | Buy | 20,000 | $1.41 | 28,200 |
|
Sequenom Inc SQNM
Common Stock
|
2015-12-14 | Buy | 20,000 | $1.26 | 25,200 |
|
Sequenom Inc SQNM
Common Stock
|
2015-12-14 | Buy | 428,000 | $1.30 | 556,400 |
|
Sequenom Inc SQNM
Common Stock
|
2015-12-10 | Buy | 253,565 | $1.36 | 344,848 |
|
Sequenom Inc SQNM
Common Stock
|
2015-12-09 | Buy | 213,000 | $1.32 | 281,160 |
|
Sequenom Inc SQNM
Common Stock
|
2015-12-08 | Buy | 325,000 | $1.24 | 403,000 |
| showing 20 of 32 most recent transactions | |||||